Chen Qiyu Elected as First Chairman-in-Office of China PIRDA
The third session of the 9th members conference of China Pharmaceu
tical Industry Research and Development Association (China PIRDA) was held in Beijing on June 1, 2012. Sang Guowei, vice chairman of the standing committee of the National People’s Congress, and Chen Zhu, minister of the Ministry of Health, attended the meeting and delivered speech respectively.
After reviewed by the conference, Chen Qiyu, vice chairman of China PIRDA and Chairman of Shanghai Fosun Pharmaceutical（Group） Co., Ltd., was elected as chairman-in-office of China PIRDA in 2012.
Sun Piaoyang, chairman of Jiangsu Hengrui Medicine Co., Ltd., Ren Jinsheng, chairman of Simcere Pharmaceutical Group Co., Ltd., Shi Chengyi, secretary to chairman of China National Pharmaceutical Group Corporation Ltd., were respectively elected as vice chairman of China PIRDA. In addition, Shenyang Sunshine Pharmaceutical Co., Ltd., BaiGene(Beijing) Biological Technology Co., Ltd., Guangzhou Xiangxue Pharmaceutical Co., Ltd., Yabao Pharmaceutical Co, Ltd., Changzhou Fangyuan Pharmaceuticl Co., Ltd., Henan Tailong Pharmaceutical Co., Ltd. And Shanghai Tofflon Science and Technology Co., Ltd. were admitted as members.
“It is the first time for China PIRDA to adopt the chairman-in-office system, a common practice internationally. This is an exciting exploration. At the same time, it also gives our member units more opportunities to develop and more responsibilities to bear.” As Chen Qiyu suggested, China PIRDA will make further efforts and gather powers to make greater contributions in advancing construction of a enterprise-based and market-oriented pharmaceutical innovation system that integrates the industry with education and research, improve competitiveness of the entire pharmaceutical industry, promote globalization of China’s pharmaceutical industry, and realize its sustainable development.
tical Industry Research and Development Association (China PIRDA) was held in Beijing on June 1, 2012. Sang Guowei, vice chairman of the standing committee of the National People’s Congress, and Chen Zhu, minister of the Ministry of Health, attended the meeting and delivered speech respectively.
After reviewed by the conference, Chen Qiyu, vice chairman of China PIRDA and Chairman of Shanghai Fosun Pharmaceutical（Group） Co., Ltd., was elected as chairman-in-office of China PIRDA in 2012.
Sun Piaoyang, chairman of Jiangsu Hengrui Medicine Co., Ltd., Ren Jinsheng, chairman of Simcere Pharmaceutical Group Co., Ltd., Shi Chengyi, secretary to chairman of China National Pharmaceutical Group Corporation Ltd., were respectively elected as vice chairman of China PIRDA. In addition, Shenyang Sunshine Pharmaceutical Co., Ltd., BaiGene(Beijing) Biological Technology Co., Ltd., Guangzhou Xiangxue Pharmaceutical Co., Ltd., Yabao Pharmaceutical Co, Ltd., Changzhou Fangyuan Pharmaceuticl Co., Ltd., Henan Tailong Pharmaceutical Co., Ltd. And Shanghai Tofflon Science and Technology Co., Ltd. were admitted as members.
“It is the first time for China PIRDA to adopt the chairman-in-office system, a common practice internationally. This is an exciting exploration. At the same time, it also gives our member units more opportunities to develop and more responsibilities to bear.” As Chen Qiyu suggested, China PIRDA will make further efforts and gather powers to make greater contributions in advancing construction of a enterprise-based and market-oriented pharmaceutical innovation system that integrates the industry with education and research, improve competitiveness of the entire pharmaceutical industry, promote globalization of China’s pharmaceutical industry, and realize its sustainable development.
tical Industry Research and Development Association (China PIRDA) was held in Beijing on June 1, 2012. Sang Guowei, vice chairman of the standing committee of the National People’s Congress, and Chen Zhu, minister of the Ministry of Health, attended the meeting and delivered speech respectively.
After reviewed by the conference, Chen Qiyu, vice chairman of China PIRDA and Chairman of Shanghai Fosun Pharmaceutical（Group） Co., Ltd., was elected as chairman-in-office of China PIRDA in 2012.
Sun Piaoyang, chairman of Jiangsu Hengrui Medicine Co., Ltd., Ren Jinsheng, chairman of Simcere Pharmaceutical Group Co., Ltd., Shi Chengyi, secretary to chairman of China National Pharmaceutical Group Corporation Ltd., were respectively elected as vice chairman of China PIRDA. In addition, Shenyang Sunshine Pharmaceutical Co., Ltd., BaiGene(Beijing) Biological Technology Co., Ltd., Guangzhou Xiangxue Pharmaceutical Co., Ltd., Yabao Pharmaceutical Co, Ltd., Changzhou Fangyuan Pharmaceuticl Co., Ltd., Henan Tailong Pharmaceutical Co., Ltd. And Shanghai Tofflon Science and Technology Co., Ltd. were admitted as members.
“It is the first time for China PIRDA to adopt the chairman-in-office system, a common practice internationally. This is an exciting exploration. At the same time, it also gives our member units more opportunities to develop and more responsibilities to bear.” As Chen Qiyu suggested, China PIRDA will make further efforts and gather powers to make greater contributions in advancing construction of a enterprise-based and market-oriented pharmaceutical innovation system that integrates the industry with education and research, improve competitiveness of the entire pharmaceutical industry, promote globalization of China’s pharmaceutical industry, and realize its sustainable development.
tical Industry Research and Development Association (China PIRDA) was held in Beijing on June 1, 2012. Sang Guowei, vice chairman of the standing committee of the National People’s Congress, and Chen Zhu, minister of the Ministry of Health, attended the meeting and delivered speech respectively.
After reviewed by the conference, Chen Qiyu, vice chairman of China PIRDA and Chairman of Shanghai Fosun Pharmaceutical（Group） Co., Ltd., was elected as chairman-in-office of China PIRDA in 2012.
Sun Piaoyang, chairman of Jiangsu Hengrui Medicine Co., Ltd., Ren Jinsheng, chairman of Simcere Pharmaceutical Group Co., Ltd., Shi Chengyi, secretary to chairman of China National Pharmaceutical Group Corporation Ltd., were respectively elected as vice chairman of China PIRDA. In addition, Shenyang Sunshine Pharmaceutical Co., Ltd., BaiGene(Beijing) Biological Technology Co., Ltd., Guangzhou Xiangxue Pharmaceutical Co., Ltd., Yabao Pharmaceutical Co, Ltd., Changzhou Fangyuan Pharmaceuticl Co., Ltd., Henan Tailong Pharmaceutical Co., Ltd. And Shanghai Tofflon Science and Technology Co., Ltd. were admitted as members.
“It is the first time for China PIRDA to adopt the chairman-in-office system, a common practice internationally. This is an exciting exploration. At the same time, it also gives our member units more opportunities to develop and more responsibilities to bear.” As Chen Qiyu suggested, China PIRDA will make further efforts and gather powers to make greater contributions in advancing construction of a enterprise-based and market-oriented pharmaceutical innovation system that integrates the industry with education and research, improve competitiveness of the entire pharmaceutical industry, promote globalization of China’s pharmaceutical industry, and realize its sustainable development.